Transactions in Connection With Share Buy-back Program Genmab
Yahoo FinanceApr 22 03:30 ET
Genmab Announces Net Sales of DARZALEX (Daratumumab) for First Quarter of 2024
Yahoo FinanceApr 16 06:24 ET
Genmab to Purchase US-based Biotech Company ProfoundBio for $1.8 Billion in All-cash Deal
Seeking AlphaApr 3 04:17 ET
Genmab to Broaden and Strengthen Oncology Portfolio With Acquisition of ProfoundBio
Yahoo FinanceApr 3 01:34 ET
Completion of Share Buy-back Program
Yahoo FinanceMar 18 05:49 ET
Genmab Announces Initiation of Share Buy-Back Program
Yahoo FinanceMar 15 08:16 ET
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Yahoo FinanceMar 13 16:53 ET
Passing of Genmab A/S' Annual General Meeting
Yahoo FinanceMar 13 11:13 ET
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Yahoo FinanceFeb 27 15:42 ET
Transactions in Connection With Share Buy-back Program
Yahoo FinanceFeb 26 05:21 ET
BTIG Analyst Rates Genmab as 'Buy' Citing Solid Financials and Strategic Growth Moves
TipRanksNov 8, 2023 01:09 ET
Argenx, Genmab in Pact to Study Antibody Therapies for Immunology and Oncology
Seeking AlphaApr 17, 2023 06:07 ET
AbbVie Pins Hopes on Newer Drugs and Deals to Face Humira Knockoffs – WSJ
Seeking AlphaFeb 6, 2023 07:05 ET
Genmab Files for Approval of Blood Cancer Therapy Epcoritamab in Japan
Seeking AlphaDec 21, 2022 08:38 ET
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
Yahoo FinanceNov 17, 2022 14:27 ET
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
Yahoo FinanceNov 17, 2022 11:21 ET
BioNTech, Genmab expand pact to develop cancer immunotherapies
BioNTech (NASDAQ:BNTX) and Genmab (GMAB) are expanding their collaboration to develop and commercialize novel immunotherapies to treat patients with cancer. Under the new agreement, the companies will
Seeking AlphaAug 5, 2022 08:27 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 17, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,302 shares as a consequence of the exercise of employee warrants. The increase
GlobeNewswireMay 17, 2022 14:38 ET
J&J's Janssen wins arbitration versus Genmab over royalty payments for Darzalex
Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to ca
Seeking AlphaApr 8, 2022 06:16 ET
No Data
No Data